Literature DB >> 8349943

Defective interleukin-2 and interferon-gamma gene expression in response to antigen in a subgroup of patients with common variable immunodeficiency.

M B Fischer1, I Hauber, E Vogel, H M Wolf, J W Mannhalter, M M Eibl.   

Abstract

Patients with common variable immunodeficiency (CVID) are heterogeneous in the clinical manifestations of the disease and in the underlying mechanisms leading to the immunodeficiency. The impairment of B-cell function can be due to an intrinsic defect of the B cells, a deficiency in the function of the antigen-presenting cell, or a dysfunction in the course of T-cell activation. In the present report we have focused our attention on T-lymphocyte activation in three patients with CVID. Numbers of T and B cells, as well as CD4 and CD8 T cell subsets, were within the normal range. The patients' B cells secreted IgM but did not secrete IgG and IgA in response to B-cell stimuli in vitro. Addition of allogeneic T cells was followed by an increase in IgM production but had no effect on the other immunoglobulin isotypes. Examination of T-cell function revealed impaired proliferative response, interleukin-2 (IL-2) and interferon-gamma gene expression and IL-2 release after antigenic stimulation, whereas T-cell proliferation, as well as IL-2 gene expression and release in response to stimulation via anti-CD3, were comparable to those of healthy control subjects. Anti-CD3-induced IFN-gamma gene activation in T cells from two patients was comparable to that of control subjects, whereas T cells from the third patient showed reduced expression of IFN-gamma mRNA. In contrast to the decreased IL-2 and IFN-gamma mRNA levels, IL-2R transcripts examined in parallel were normal in CVID T cells on stimulation with antigen. The defect in IL-2 and IFN-gamma mRNA expression after stimulation with antigen, but not with anti-CD3, suggests an abnormality confined to T-cell activation by the T-cell receptor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8349943     DOI: 10.1016/0091-6749(93)90178-i

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  12 in total

1.  International Consensus Document (ICON): Common Variable Immunodeficiency Disorders.

Authors:  Francisco A Bonilla; Isil Barlan; Helen Chapel; Beatriz T Costa-Carvalho; Charlotte Cunningham-Rundles; M Teresa de la Morena; Francisco J Espinosa-Rosales; Lennart Hammarström; Shigeaki Nonoyama; Isabella Quinti; John M Routes; Mimi L K Tang; Klaus Warnatz
Journal:  J Allergy Clin Immunol Pract       Date:  2015-11-07

Review 2.  Pathogenesis and treatment of gastrointestinal disease in antibody deficiency syndromes.

Authors:  Shradha Agarwal; Lloyd Mayer
Journal:  J Allergy Clin Immunol       Date:  2009-08-08       Impact factor: 10.793

3.  Identification of a subset of common variable immunodeficiency patients with impaired B-cell protein tyrosine phosphorylation.

Authors:  R Schwartz; Y B Porat; Z Handzel; Z Sthoeger; B Z Garty; R Confino-Cohen; J Levy; I Zan-Bar
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

Review 4.  Common variable immunodeficiency: clinical aspects and recent progress in identifying the immunological defect(s).

Authors:  M M Eibl; H M Wolf
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

5.  Common variable immunodeficiency (CVID) and MxA-protein expression in blood leucocytes.

Authors:  J A Rump; D Jakschiess; U Walker; M Schlesier; P von Wussow; H H Peter
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

6.  The costimulatory signal CD28 is fully functional but cannot correct the impaired antigen response in T cells of patients with common variable immunodeficiency.

Authors:  M B Fischer; H M Wolf; H Eggenbauer; V Thon; E Vogel; J Lokaj; J Litzman; J W Mannhalter; M M Eibl
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

Review 7.  Common variable immunodeficiency: etiological and treatment issues.

Authors:  Sean Deane; Carlo Selmi; Stanley M Naguwa; Suzanne S Teuber; M Eric Gershwin
Journal:  Int Arch Allergy Immunol       Date:  2009-07-01       Impact factor: 2.749

8.  A double-blind, placebo-controlled, crossover therapy study with natural human IL-2 (nhuIL-2) in combination with regular intravenous gammaglobulin (IVIG) infusions in 10 patients with common variable immunodeficiency (CVID).

Authors:  J A Rump; A Jahreis; M Schlesier; S Stecher; H H Peter
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

9.  Defective integration of activating signals derived from the T cell receptor (TCR) and costimulatory molecules in both CD4+ and CD8+ T lymphocytes of common variable immunodeficiency (CVID) patients.

Authors:  V Thon; H M Wolf; M Sasgary; J Litzman; A Samstag; I Hauber; J Lokaj; M M Eibl
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

Review 10.  Cytokines in common variable immunodeficiency as signs of immune dysregulation and potential therapeutic targets - a review of the current knowledge.

Authors:  Farnaz Najmi Varzaneh; Bärbel Keller; Susanne Unger; Asghar Aghamohammadi; Klaus Warnatz; Nima Rezaei
Journal:  J Clin Immunol       Date:  2014-05-15       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.